50% OF THE RENAL TRANSPLANT PATIENTS THAT CAN NOT REACH THERAPEUTIC MYCOPHENOLIC ACID LEVELS WITH MMF BECAUSE OF GI INTOLERANCE, ACHIEVED THERAPEUTIC LEVELS WITH EC-MPS. | Publicación